Previous close | 8.25 |
Open | 8.15 |
Bid | 7.92 x 100 |
Ask | 8.00 x 100 |
Day's range | 7.94 - 8.31 |
52-week range | 7.72 - 27.48 |
Volume | |
Avg. volume | 1,080,779 |
Market cap | 1.075B |
Beta (5Y monthly) | 0.41 |
PE ratio (TTM) | N/A |
EPS (TTM) | -4.59 |
Earnings date | 02 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 32.29 |
SAN FRANCISCO, April 18, 2024--Vir Biotechnology, Inc. ("Vir" or "the Company", Nasdaq: VIR) today announced the nomination of Norbert Bischofberger, Ph.D. and Ramy Farid, Ph.D. to its Board of Directors (the "Board") at its upcoming annual meeting of stockholders on May 29, 2024 (the "Annual Meeting"). If elected, each of Drs. Bischofberger and Farid will join the Board on such date.
SAN FRANCISCO, April 11, 2024--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will provide a corporate update and report financial results for the first quarter ended March 31, 2024, on May 2, 2024. The Company will host a conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time on May 2, 2024.
Vir Biotechnology Inc (NASDAQ:VIR), a company focused on the research and development of treatments for serious infectious diseases, has reported an insider sell according to a recent SEC filing.